Bukwang Pharmaceutical Co., Ltd. (003000.KS)
KRW 4745.0
(-1.35%)
KRW 4745.0
(-1.35%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 56.83 Billion KRW | 47.21% |
| 2022 | 38.6 Billion KRW | -1.75% |
| 2021 | 39.29 Billion KRW | -23.51% |
| 2020 | 51.37 Billion KRW | 16.4% |
| 2019 | 44.13 Billion KRW | 28.98% |
| 2018 | 34.21 Billion KRW | -13.62% |
| 2017 | 39.61 Billion KRW | 0.66% |
| 2016 | 39.35 Billion KRW | 2.72% |
| 2015 | 38.31 Billion KRW | 26.14% |
| 2014 | 30.37 Billion KRW | 4.27% |
| 2013 | 29.12 Billion KRW | 11.56% |
| 2012 | 26.1 Billion KRW | -11.82% |
| 2011 | 29.6 Billion KRW | -11.0% |
| 2010 | 33.26 Billion KRW | -10.85% |
| 2009 | 37.31 Billion KRW | 1.49% |
| 2008 | 36.76 Billion KRW | 9.89% |
| 2007 | 33.46 Billion KRW | 75.27% |
| 2006 | 19.09 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 50.68 Billion KRW | -3.63% |
| 2024 Q1 | 52.58 Billion KRW | -7.46% |
| 2023 Q2 | 46.49 Billion KRW | 3.55% |
| 2023 FY | 56.83 Billion KRW | 47.21% |
| 2023 Q4 | 56.83 Billion KRW | -7.81% |
| 2023 Q1 | 44.9 Billion KRW | 16.31% |
| 2023 Q3 | 61.64 Billion KRW | 32.59% |
| 2022 Q3 | 40.95 Billion KRW | -7.3% |
| 2022 Q2 | 44.18 Billion KRW | 7.19% |
| 2022 Q1 | 41.22 Billion KRW | 4.91% |
| 2022 FY | 38.6 Billion KRW | -1.75% |
| 2022 Q4 | 38.6 Billion KRW | -5.74% |
| 2021 Q2 | 53.11 Billion KRW | -2.65% |
| 2021 FY | 39.29 Billion KRW | -23.51% |
| 2021 Q3 | 48.44 Billion KRW | -8.78% |
| 2021 Q4 | 39.29 Billion KRW | -18.9% |
| 2021 Q1 | 54.55 Billion KRW | 6.19% |
| 2020 FY | 51.37 Billion KRW | 16.4% |
| 2020 Q2 | 55.27 Billion KRW | 5.48% |
| 2020 Q3 | 55.12 Billion KRW | -0.27% |
| 2020 Q4 | 51.37 Billion KRW | -6.8% |
| 2020 Q1 | 52.4 Billion KRW | 18.72% |
| 2019 Q1 | 41.24 Billion KRW | 20.54% |
| 2019 Q4 | 44.13 Billion KRW | -0.42% |
| 2019 FY | 44.13 Billion KRW | 28.98% |
| 2019 Q2 | 42.01 Billion KRW | 1.86% |
| 2019 Q3 | 44.32 Billion KRW | 5.49% |
| 2018 Q1 | 42.53 Billion KRW | 7.38% |
| 2018 FY | 34.21 Billion KRW | -13.62% |
| 2018 Q4 | 34.21 Billion KRW | -12.57% |
| 2018 Q3 | 39.14 Billion KRW | -5.55% |
| 2018 Q2 | 41.43 Billion KRW | -2.58% |
| 2017 Q2 | 41.07 Billion KRW | -1.13% |
| 2017 Q1 | 41.54 Billion KRW | 5.58% |
| 2017 Q4 | 39.61 Billion KRW | 0.19% |
| 2017 FY | 39.61 Billion KRW | 0.66% |
| 2017 Q3 | 39.53 Billion KRW | -3.74% |
| 2016 Q4 | 39.35 Billion KRW | -6.35% |
| 2016 FY | 39.35 Billion KRW | 2.72% |
| 2016 Q1 | 40.1 Billion KRW | 4.68% |
| 2016 Q2 | 41.83 Billion KRW | 4.32% |
| 2016 Q3 | 42.02 Billion KRW | 0.44% |
| 2015 Q1 | 31.45 Billion KRW | 3.58% |
| 2015 FY | 38.31 Billion KRW | 26.14% |
| 2015 Q4 | 38.31 Billion KRW | 16.22% |
| 2015 Q3 | 32.96 Billion KRW | 3.21% |
| 2015 Q2 | 31.93 Billion KRW | 1.52% |
| 2014 Q4 | 30.37 Billion KRW | 2.75% |
| 2014 FY | 30.37 Billion KRW | 4.27% |
| 2014 Q2 | 27.49 Billion KRW | 0.0% |
| 2014 Q3 | 29.55 Billion KRW | 7.5% |
| 2013 Q4 | 29.12 Billion KRW | 0.0% |
| 2013 FY | 29.12 Billion KRW | 11.56% |
| 2013 Q1 | 29.66 Billion KRW | 13.62% |
| 2012 Q4 | 26.1 Billion KRW | 18.89% |
| 2012 Q1 | 24.9 Billion KRW | 0.0% |
| 2012 FY | 26.1 Billion KRW | -11.82% |
| 2012 Q2 | 23.84 Billion KRW | -4.27% |
| 2012 Q3 | 21.96 Billion KRW | -7.9% |
| 2011 FY | 29.6 Billion KRW | -11.0% |
| 2011 Q3 | 30.09 Billion KRW | 2.57% |
| 2011 Q1 | 33.26 Billion KRW | -8.98% |
| 2011 Q2 | 29.34 Billion KRW | -11.79% |
| 2010 Q3 | 37.88 Billion KRW | 5.09% |
| 2010 Q4 | 36.55 Billion KRW | -3.52% |
| 2010 Q2 | 36.05 Billion KRW | -3.39% |
| 2010 Q1 | 37.31 Billion KRW | -1.92% |
| 2010 FY | 33.26 Billion KRW | -10.85% |
| 2009 Q4 | 38.04 Billion KRW | -4.25% |
| 2009 Q3 | 39.73 Billion KRW | 2.88% |
| 2009 Q2 | 38.62 Billion KRW | 0.0% |
| 2009 FY | 37.31 Billion KRW | 1.49% |
| 2008 Q4 | 40.82 Billion KRW | 10.62% |
| 2008 Q2 | 35.83 Billion KRW | 0.0% |
| 2008 Q3 | 36.9 Billion KRW | 2.98% |
| 2008 FY | 36.76 Billion KRW | 9.89% |
| 2007 FY | 33.46 Billion KRW | 75.27% |
| 2007 Q2 | 21.92 Billion KRW | 0.0% |
| 2007 Q3 | 24.34 Billion KRW | 11.0% |
| 2007 Q4 | 33.03 Billion KRW | 35.72% |
| 2006 FY | 19.09 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -28.718% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 51.777% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 37.661% |
| HANDOK Inc. | 94.46 Billion KRW | 39.838% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -167.531% |
| Yuhan Corporation | 284.75 Billion KRW | 80.042% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 51.139% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -249.548% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 80.322% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -75.493% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 7.927% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -191.789% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -87.686% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -17.549% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -28.718% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -81.916% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -61.562% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -18.084% |
| JW Holdings Corporation | 147.58 Billion KRW | 61.493% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 32.842% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 78.261% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 46.431% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -5.394% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -110.504% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -74.806% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 48.226% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -28.718% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 69.873% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 76.472% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 46.431% |
| Yuhan Corporation | 284.75 Billion KRW | 80.042% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 54.636% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 8.316% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 78.128% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 46.431% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 28.606% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -15.648% |
| CKD Bio Corp. | 69.08 Billion KRW | 17.733% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 45.915% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 19.612% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -5.131% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -5.394% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 70.82% |
| Boryung Corporation | 189.8 Billion KRW | 70.058% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 7.927% |
| JW Lifescience Corporation | 23.39 Billion KRW | -142.886% |